RecruitingPhase 1Phase 2NCT06492850

Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa

A Phase I/II Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of FT-002 Subretinal Injection in Subjects With RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa.

Sponsor

Frontera Therapeutics

Enrollment

32 participants

Start Date

Apr 1, 2024

Study Type

INTERVENTIONAL

Conditions

X-Linked Retinitis Pigmentosa (XLRP)

Summary

The aim of this study was to evaluate the safety, tolerability, and efficacy of one-time subretinal injection of FT-002 in male subjects (8-45 years of age) with RPGR (Retinitis Pigmentosa GTPase Regulator) gene mutation-associated X-linked retinitis pigmentosa, of XLRP. This study includes Phase I (dose escalation phase) and Phase II (dose expansion phase).

Eligibility

Sex: MALEMin Age: 8 YearsMax Age: 45 Years

Inclusion Criteria3

Subjects that are willing and able to follow study procedures including scheduled visits, treatment plan, and laboratory tests, and sign a written informed consent form;
Age: Phase I dose escalation stage, 18-45 years old male (including boundary value) at the time of signing the ICF; Phase II dose extension stage, males 8-45 years old (including boundary values) at the time of signing the ICF;
Clinically diagnosed XLRP, the main symptoms include but are not limited to night blindness, visual field loss, vision loss, etc.;

Exclusion Criteria1

Have other retinal degenerative diseases, such as retinal degeneration caused by other known Inherited retinal disease gene variants or previously received an gene therapy product.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.